SARM1 activation further depleted the residual NAD in FK866-treated cells, again suggesting that reversible activation of SARM1 might be a viable strategy for enhancing the efficacy of FK866 in glioblastoma therapy. This evidence concerns the gene SARM1 and glioblastoma.